|Day Low/High||2.43 / 2.48|
|52 Wk Low/High||3.30 / 40.00|
Computational Subgroup Analysis of Phase 3 ONTIME Trial Provides Insights into Clinical Response to Rigosertib in Higher-risk MDS
Pivotal Randomized Trial in 1st-line MDS Patients will Assess Overall Response Rate as Approval Endpoint
These under-$10 stocks are within range of triggering breakout trades.
Here's a technical look at how to trade several under-$10 stocks that were making big moves to the upside recently.
Global Phase 3 INSPIRE Trial of Rigosertib in Higher-Risk Myelodysplastic Syndromes Now Active in More than 90 Sites
Interim Data from Fully-Enrolled Phase 2 Trial
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Presentation highlighted during discussion session